References
1.Shu Z , Yang Y , Yang L , Jiang H , Yu X , Wang Y . Cardioprotective effects of dihydroquercetin against ischemia reperfusion injury by inhibiting oxidative stress and endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway. Food Funct. 2019;10(1):203-215. doi:10.1039/c8fo01256c

2.Kim, Y.J., Choi, S.E., Lee, M.W. and Lee, C.S. (2008), Taxifolin glycoside inhibits dendritic cell responses stimulated by lipopolysaccharide and lipoteichoic acid. Journal of Pharmacy and Pharmacology, 60: 1465-1472.

3.Pan S, Zhao X, Ji N, et al., Inhibitory effect of taxifolin on mast cell activation and mast cell-mediated allergic inflammatory response, International Immunopharmacology, Volume 71, 2019, Pages 205-214

4.Kolhir VK, Bykov VA, Teselkin YO, et al. Use of a new antioxidant diquertin as an adjuvant in the therapy of patients with acute pneumonia. Phytotherapy Research. 1998;12:606-8.

5.Guo H, Zhang X, Cui Y, et al., Taxifolin protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload, Toxicology and Applied Pharmacology, Volume 287, Issue 2, 2015, Pages 168-177

6.Saito, S., Yamamoto, Y., Maki, T. et al. Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy. acta neuropathol commun 5, 26 (2017). https://doi.org/10.1186/s40478-017-0429-5

7.Yun J, Bae H, Choi SE, et al. Taxifolin Glycoside Blocks Human ether-a-go-go Related Gene K(+) Channels. Korean J Physiol Pharmacol. 2013;17(1):37-42. doi:10.4196/kjpp.2013.17.1.37

8.Liu F, Ma Y, Xu Y,  Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Volume 20, Number 4, 2020, pp. 599-608(10)

9.Chen Y, Deuster P. Comparison of quercetin and dihydroquercetin: antioxidant-independent actions on erythrocyte and platelet membrane. Chem Biol Interact. 2009;182(1):7-12. doi:10.1016/j.cbi.2009.06.007

10.Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2(4):659-668.

11.Makena, Patrudu S.; Pierce, Samuel C.; Chung, King-Thom; Sinclair, Scott E. (2009). "Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP-2 uvrA". Environmental and Molecular Mutagenesis. 50 (6): 451–9. doi:10.1002/em.20487

12.Kozlov, V., Azizov, G., et al. Capilar in correction of microcirculatory disturbances. Vrach [Physician] 6 (2006)

13.Kostyuk VA, Kraemer T, Sies H, Schewe T. Myeloperoxidase/nitrite-mediated lipid peroxidation of low-density lipoprotein as modulated by flavonoids. FEBS Lett. 2003 Feb 27;537(1-3):146-50.

14.Tikhonov VP, Makarova MN, Zajtseva MA, Makarov VG. Efficacy of (±)-taxifolin from Larix sibirica (Mûnchh.) Ledeb. on blood pressure in experiments in vivo. Planta Med. 2006;72:174

15.Theriault, A., Wang, Q., et al. J Lipid Res, 41 (2000) 1969-1979

16.Kolhir, V.K., Bykov, V.A., et al. Phytotherapy Research, 10 (1996) 478-482)

17.Kolhir VK, Bykov VA, Teselkin YO, et al. Use of a new antioxidant diquertin as an adjuvant in the therapy of patients with acute pneumonia. Phytotherapy Research. 1998;12:606-8.

18.Potapovich AI, Kostyuk VA. Comparative study of antioxidant properties and cytoprotective activity of flavonoids. Biochemistry (Mosc.). 2003 May;68(5):514-9.

19.Haraguchi H, Mochida Y, Sakai S, et al. Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis. Biosci Biotechnol Biochem. 1996 Jun;60(6):945-8.

20.Kostyuk VA, Potapovich AI. Antiradical and chelating effects in flavonoid protection against silica-induced cell injury. Arch Biochem Biophys. 1998 Jul 1;355(1):43-8.

21.Gupta, et al. Japan J Pharmacol, 21 (1971) 377- 382).

22.Kolhir VK, Bykov VA, Teselkin YO, et al. Use of a new antioxidant diquertin as an adjuvant in the therapy of patients with acute pneumonia. Phytotherapy Research. 1998;12:606-8.

23.Dok-Go, H., Lee, K.H., Kim, H.J, et al. Brain Research, 965 (2003) 130-136

24.Biziagos E, Crance JM, Passagot J, Deloince R. Effect of antiviral substances on hepatitis A virus replication in vitro. J Med Virol. 1987 May;22(1):57-66

25.Liu F, Ma Y, Xu Y,  Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Volume 20, Number 4, 2020, pp. 599-608(10)

26.SunJ, Ge F, Wang Y, et al. Taxifolin is a rat and human 11β-hydroxysteroid dehydrogenase 1 inhibitor as a possible drug to treat the metabolic syndrome. Journal of Functional Foods, Volume 49, 2018, Pages 181-187,

27.van Oostrom AJ, van Wijk JP, Sijmonsma TP, Rabelink TJ, Castro CM. Increased expression of activation markers on monocytes and neutrophils in type 2 diabetes. Neth J Med. 2004 Oct;62(9):320-5.

28.Fedosova NF, Alisievich SV, Lyadov KV, et al. Mechanisms underlying diquertin-mediated regulation of neutrophil function in patients with non-insulin-dependent diabetes mellitus. Bull Exp Biol Med. 2004 Feb;137(2):143-6.

29.Davudova, T.B., Zoloeva, E.I. Free-radical oxidation in patients with diabetes mellitus taking diquertin. International Journal of Applied and Fundamental Research, 7 (2009).

30.Harper KA, Morton AD, Rolfe EJ. Phenolic compounds of black currant juice and their effect on ascorbic acid. III Mechanism of ascorbic acid oxidation and its inhibition by flavonoids. J Food Tech. 1969;4:255-67

31.Nijveldt RJ, van NE, van Hoorn DE, et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001 Oct;74(4):418-25.

32.Plotnikov MB, Plotnikov DM, Aliev OI, et al. Hemorheological and antioxidant effects of Ascovertin in patients with sclerosis of cerebral arteries. Clin Hemorheol Microcirc. 2004;30(3-4):449-52.

33.Plotnikov MB, Plotnikov DM, Alifirova VM, et al. Clinical efficacy of a novel hemorheological drug ascovertin in patients with vascular encephalopathy. Zh Nevrol Psikhiatr Im SS Korsakova. 2004;104(12):33-7.

34.Teselkin Yu O. et al., Dihydroquercetin as a mean of antioxidant defence in rats with tetrachloromethane hepatitis, Phytotherapy Research, 11 May 2000, vol. 14, issue 3, 160-162.

35.Wang Y.H. et al., Taxifolin ameliorate cerebral ischemia-reperfusion injury in rat through its anti-oxidative effect and modulation pf NF-kappa B activation, J. Biomed. Scien., 2006 Jan, 13(1): 127-41. 

36.Wang Y.H. et al., Prevention of macrophage adhesion molecule-1dependant neutrophil firm adhesion by taxifolin through impairment of protein kinase-dependant NADPH oxidase activation and antagonism of G protein-mediated calcium influx, Biochem. Pharmacol., 2004 June 15, 67(12): 2251-62.

37.Ibrahim Ahiskali, Can Lokman Pinar, Murat Kiki, Murat Cankaya, Celaleddin Semih Kunak & Durdu Altuner (2019) Effect of taxifolin on methanol-induced oxidative and inflammatory optic nerve damage in rats, Cutaneous and Ocular Toxicology,38:4, 384-389, DOI: 10.1080/15569527.2019.1637348

38.Xiaobin Xie, Youzhi Tang; Taxifolin protects retinal pigment epithelium cells against oxidative stress induced apoptosis Invest. Ophthalmol. Vis. Sci. 2017;58(8):1979.

39.Ibrahim Ahiskali, Can Lokman Pinar, Murat Kiki, Renad Mammadov, Asli Ozbek Bilgin, Ahmet Hacimuftuoglu, Murat Cankaya, Ferda Keskin Cimen & Durdu Altuner (2019) Effect of taxifolin on development of retinopathy in alloxan-induced diabetic rats, Cutaneous and Ocular Toxicology, 38:3, 227-232, DOI: 10.1080/15569527.2019.1588289

40.Biziagos E, Crance JM, Passagot J, Deloince R. Effect of antiviral substances on hepatitis A virus replication in vitro. J Med Virol. 1987;22(1):57-66. doi:10.1002/jmv.1890220108